SITC Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. The Heme Subcommittee was developed to generate consensus statements specifically for hematological cancers.
Due to advances in the field, the Heme Subcommittee was divided into three distinct subcommittees in 2018: 1) Acute Leukemia, 2) Lymphoma, and 3) Multiple Myeloma.